Apolipoprotein E, Amyloid-clearance and therapeutic opportunities in Alzheimer's disease

Alzheimer's Research and Therapy

Volumn 4, Issue 4, 2012, Pages

  Kline, Adam ^a  

^a EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BAPINEUZUMAB; CLUSTERIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST;

ALLELE; ALZHEIMER DISEASE; AMYLOIDOSIS; BLOOD BRAIN BARRIER; GENOTYPE; HETEROZYGOTE; INNATE IMMUNITY; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN INTERACTION; REVIEW; RISK FACTOR;

EID: 84864806543     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt135     Document Type: Review

References (65)

1. Origin of the distinction between Alzheimer's disease and senile dementia: how history can clarify nosology. Amaducci LA, Rocca WA, Schoenberg BS, Neurology 1986 36 1497 1499 10.1212/WNL.36.11.1497 3531918
2. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, Thomas-Anterion C, Michon A, Martin C, Charbonnier F, Raux G, Camuzat A, Penet C, Mesnage V, Martinez M, Clerget-Darpoux F, Brice A, Frebourg T, Am J Hum Genet 1999 65 664 670 10.1086/302553 10441572
3. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH, Alzheimers Dement 2011 7 280 292 10.1016/j.jalz.2011.03.003 21514248
4. APP processing in Alzheimer's disease. Zhang YW, Thompson R, Zhang H, Xu H, Mol Brain 2011 4 3 10.1186/1756-6606-4-3 21214928
5. Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. Weggen S, Beher D, Alzheimer's Res Ther 2012 4 9 10.1186/alzrt107 22892648
6. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM, J Biol Chem 2006 281 39413 39423 10.1074/jbc.M608485200 17056594
7. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L, Science 2007 316 750 754 10.1126/science.1141736 17478722
8. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Giannakopoulos P, Herrmann FR, Bussière T, Bouras C, Kövari E, Perl DP, Morrison JH, Gold G, Hof PR, Neurology 2003 60 1495 1500 10.1212/01.WNL.0000063311.58879.01 12743238
9. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, Imagawa M, Ataka S, Wada Y, Yoshioka E, Nishizaki T, Watanabe Y, Mori H, Ann Neurol 2008 63 377 387 10.1002/ana.21321 18300294
10. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Näslund J, Lannfelt L, Nat Neurosci 2001 9 887 893 11528419
11. The toxic A oligomer and Alzheimer's disease: an emperor in need of clothes. Benilova I, Karran E, De Strooper B, Nat Neurosci 2012 15 349 357 10.1038/nn.3028 22286176
12. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW, Biochim Biophys Acta 1987 917 148 161 10.1016/0005-2760(87)90295-5 3539206
13. Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. Myers RH, Schaefer EJ, Wilson PW, D'Agostino R, Ordovas JM, Espino A, Au R, White RF, Knoefel JE, Cobb JL, McNulty KA, Beiser A, Wolf PA, Neurology 1996 46 673 677 10.1212/WNL.46.3.673 8618665
14. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Drzezga A, Grimmer T, Henriksen G, Mühlau M, Perneczky R, Miederer I, Praus C, Sorg C, Wohlschläger A, Riemenschneider M, Wester HJ, Foerstl H, Schwaiger M, Kurz A, Neurology 2009 72 1487 1494 10.1212/WNL.0b013e3181a2e8d0 19339712
15. APOE modifies the association between A load and cognition in cognitively normal older adults. Kantarci K, Lowe V, Przybelski SA, Weigand SD, Senjem ML, Ivnik RJ, Preboske GM, Roberts R, Geda YE, Boeve BF, Knopman DS, Petersen RC, Jack CR Jr, Neurology 2012 78 232 240 10.1212/WNL.0b013e31824365ab 22189452
16. APOE and APP gene variation in cortical and cerebrovascular amyloid- pathology and Alzheimer's disease: a population-based analysis. Peuralinna T, Tanskanen M, Mäkelä M, Polvikoski T, Paetau A, Kalimo H, Sulkava R, Hardy J, Lai SL, Arepalli S, Hernandez D, Traynor BJ, Singleton A, Tienari PJ, Myllykangas L, J Alzheimers Dis 2011 26 377 385 21654062
17. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. Keage HA, Carare RO, Friedland RP, Ince PG, Love S, Nicoll JA, Wharton SB, Weller RO, Brayne C, BMC Neurol 2009 9 3 10.1186/1471-2377-9-3 19144113
18. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD, J Clin Invest 1994 94 860 869 10.1172/JCI117407 8040342
19. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Wisniewski T, Castão EM, Golabek A, Vogel T, Frangione B, Am J Pathol 1994 145 1030 1035 7977635
20. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM, Proc Natl Acad Sci USA 1999 96 15233 15238 10.1073/pnas.96.26.15233 10611368
21. Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by Abeta-related peptides. Ma J, Brewer HB Jr, Potter H, Neurobiol Aging 1996 17 773 780 10.1016/0197-4580(96)00112-1 8892351
22. Blocking the apolipoprotein E/amyloid- interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. Yang J, Ji Y, Mehta P, Bates KA, Sun Y, Wisniewski T, J Alzheimers Dis 2011 24 269 285 21239853
23. Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid- in human Alzheimer brain. Jones PB, Adams KW, Rozkalne A, Spires-Jones TL, Hshieh TT, Hashimoto T, von Armin CA, Mielke M, Bacskai BJ, Hyman BT, PLoS One 2011 6 14586 10.1371/journal.pone.0014586 21297948
24. High ability of apolipoprotein E4 to stabilize amyloid- peptide oligomers, the pathological entities responsible for Alzheimer's disease. Cerf E, Gustot A, Goormaghtigh E, Ruysschaert JM, Raussens V, FASEB J 2011 25 1585 1595 10.1096/fj.10-175976 21266538
25. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid- Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, Joyner D, Hou S, Kopeikina KJ, Frosch MP, Lee VM, Holtzman DM, Hyman BT, Spires-Jones TL, Brain 2012 135 2155 2168 22637583
26. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Mahley RW, Weisgraber KH, Huang Y, Proc Natl Acad Sci USA 2006 103 5644 5651 10.1073/pnas.0600549103 16567625
27. Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. Chen HK, Liu Z, Meyer-Franke A, Brodbeck J, Miranda RD, McGuire JG, Pleiss MA, Ji ZS, Balestra ME, Walker DW, Xu Q, Jeong DE, Budamagunta MS, Voss JC, Freedman SB, Weisgraber KH, Huang Y, Mahley RW, J Biol Chem 2012 287 5253 5266 10.1074/jbc.M111.276162 22158868
28. Animal models in the drug discovery pipeline for Alzheimer's disease. Van Dam D, De Deyn PP, Br J Pharmacol 2011 164 1285 1300 10.1111/j.1476-5381.2011. 01299.x 21371009
29. Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. Raffai RL, Dong LM, Farese RV Jr, Weisgraber KH, Proc Natl Acad Sci USA 2001 98 11587 11591 10.1073/pnas.201279298 11553788
30. Introducing human APOE into A transgenic mouse models. Tai LM, Youmans KL, Jungbauer L, Yu C, Ladu MJ, Int J Alzheimers Dis 2011 2011 810981 22028984
31. Human apoE isoforms differentially regulate brain amyloid- peptide clearance. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM, Sci Transl Med 2011 3 89ra57 10.1126/scitranslmed. 3002156 21715678
32. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid- amyloidosis. Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM, J Neurosci 2011 31 18007 18012 10.1523/JNEUROSCI.3773-11.2011 22159114
33. Reducing human apolipoprotein E levels attenuates age-dependent A accumulation in mutant human amyloid precursor protein transgenic mice. Bien-Ly N, Gillespie AK, Walker D, Yoon SY, Huang Y, J Neurosci 2012 32 4803 4811 10.1523/JNEUROSCI.0033-12.2012 22492035
34. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen Y, Murphy E, Leonard S, Vasylyev D, Oganesian A, Martone RL, Pangalos MN, Reinhart PH, Jacobsen JS, Mol Cell Neurosci 2007 34 621 628 10.1016/j.mcn.2007.01.011 17336088
35. ApoE-directed therapeutics rapidly clear -amyloid and reverse deficits in AD mouse models. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE, Science 2012 335 1503 1506 10.1126/science.1217697 22323736
36. Cholesterol independent effect of LXR agonist TO-901317 on gammasecretase. Czech C, Burns MP, Vardanian L, Augustin A, Jacobsen H, Baumann K, Rebeck GW, J Neurochem 2007 101 929 936 10.1111/j.1471-4159.2007.04467.x 17472585
37. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Ye S, Huang Y, Müllendorff K, Dong L, Giedt G, Meng EC, Cohen FE, Kuntz ID, Weisgraber KH, Mahley RW, Proc Natl Acad Sci USA 2005 102 18700 18705 10.1073/pnas.0508693102 16344478
38. The impact of a novel apolipoprotein E and amyloid- protein precursor-interacting protein on the production of amyloid- Hopkins PC, Sáinz-Fuertes R, Lovestone S, J Alzheimers Dis 2011 26 239 253 21971464
39. Neprilysin regulates amyloid Beta peptide levels. Marr RA, Guan H, Rockenstein E, Kindy M, Gage FH, Verma I, Masliah E, Hersh LB, J Mol Neurosci 2004 22 5 11 10.1385/JMN:22:1-2:5 14742905
40. ApoE4-driven accumulation of intraneuronal oligomerized A42 following activation of the amyloid cascade in vivo is mediated by a gain of function. Zepa L, Frenkel M, Belinson H, Kariv-Inbal Z, Kayed R, Masliah E, Michaelson DM, Int J Alzheimers Dis 2011 792070 21350674
41. Proteolytic degradation of amyloid -protein. Saido T, Leissring MA, Cold Spring Harb Perspect Med 2012 2 006379 22675659
42. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO, Brain Pathol 2008 18 253 266 18363936
43. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. Deane R, Bell RD, Sagare A, Zlokovic BV, CNS Neurol Disord Drug Targets 2009 8 16 30 10.2174/ 187152709787601867 19275634
44. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K, J Neurosci 2003 23 29 33 12514198
45. APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice. Sharman MJ, Morici M, Hone E, Berger T, Taddei K, Martins IJ, Lim WL, Singh S, Wenk MR, Ghiso J, Buxbaum JD, Gandy S, Martins RN, J Alzheimers Dis 2010 21 403 409 20555142
46. Apolipoprotein E promotes -amyloid trafficking and degradation by modulating microglial cholesterol levels. Lee CY, Tse W, Smith JD, Landreth GE, J Biol Chem 2012 287 2032 2044 10.1074/jbc.M111.295451 22130662
47. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Holtzman DM, Herz J, Bu G, Cold Spring Harb Perspect Med 2012 2 006312 22393530
48. Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid -peptide elimination from the brain. Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA, J Neurochem 2010 115 1077 1089 10.1111/j.1471-4159.2010.07002.x 20854368
49. ApoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV, J Clin Invest 2008 118 4002 4013 10.1172/JCI36663 19033669
50. Clearance of amyloid-beta by circulating lipoprotein receptors. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV, Nat Med 2007 13 1029 1031 10.1038/nm1635 17694066
51. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial Investigators, Neurology 2009 73 2061 2070 10.1212/WNL. 0b013e3181c67808 19923550
52. Neuropathology and amyloid- spectrum in a bapineuzumab immunotherapy recipient. Roher AE, Maarouf CL, Daugs ID, Kokjohn TA, Hunter JM, Sabbagh MN, Beach TG, J Alzheimers Dis 2011 24 315 325 21263194
53. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A clearance. Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM, Neuron 2009 64 632 644 10.1016/j.neuron.2009.11.013 20005821
54. Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model. Katsouri L, Georgopoulos S, PLoS One 2011 6 21880 10.1371/journal.pone.0021880 21755005
55. Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Cao D, Fukuchi K, Wan H, Kim H, Li L, Neurobiol Aging 2006 27 1632 1643 10.1016/j.neurobiolaging.2005.09.011 16236385
56. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. Fryer JD, Demattos RB, McCormick LM, O'Dell MA, Spinner ML, Bales KR, Paul SM, Sullivan PM, Parsadanian M, Bu G, Holtzman DM, J Biol Chem 2005 280 25754 25759 10.1074/jbc.M502143200 15888448
57. Up-regulation of low density lipoprotein receptor by a novel isobenzofranone derivative, MD-700. Murakami S, Nitanai I, Uchida S, Kondo-Ohta Y, Asami Y, Kondo K, Sato M, Kawashima A, Hara H, Tomisawa K, Mei HB, Xiang CZ, Atherosclerosis 1999 146 281 290 10.1016/S0021-9150(99)00148-3 10532684
58. Alzheimer's disease genetics: current knowledge and future challenges. Hollingworth P, Harold D, Jones L, Owen MJ, Williams J, Int J Geriatr Psychiatry 2011 26 793 802 10.1002/gps.2628 20957767
59. Genetic variation at CR1 increases risk of cerebral amyloid angiopathy. Biffi A, Shulman JM, Jagiella JM, Cortellini L, Ayres AM, Schwab K, Brown DL, Silliman SL, Selim M, Worrall BB, Meschia JF, Slowik A, De Jager PL, Greenberg SM, Schneider JA, Bennett DA, Rosand J, Neurology 2012 78 334 341 10.1212/WNL.0b013e3182452b40 22262751
60. Functional links between A toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Treusch S, Hamamichi S, Goodman JL, Matlack KE, Chung CY, Baru V, Shulman JM, Parrado A, Bevis BJ, Valastyan JS, Han H, Lindhagen-Persson M, Reiman EM, Evans DA, Bennett DA, Olofsson A, DeJager PL, Tanzi RE, Caldwell KA, Caldwell GA, Lindquist S, Science 2011 334 1241 1245 10.1126/science.1213210 22033521
61. Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. Kivipelto M, Rovio S, Ngandu T, Kåreholt I, Eskelinen M, Winblad B, Hachinski V, Cedazo-Minguez A, Soininen H, Tuomilehto J, Nissinen A, J Cell Mol Med 2008 12 2762 2771 10.1111/j.1582-4934.2008.00296.x 18318693
62. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. ADAPT Research Group, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M, Arch Neurol 2008 65 896 905 18474729
63. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M, Curr Alzheimer Res 2011 8 592 606 10.2174/156720511796391935 21592048
64. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A, LEADe Investigators, Neurology 2010 74 956 964 10.1212/WNL.0b013e3181d6476a 20200346
65. APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer's disease transgenics. Vitek MP, Christensen DJ, Wilcock D, Davis J, Van Nostrand WE, Li FQ, Colton CA, Neurodegenerative Dis 2012 10 122 126 10.1159/000334914 22326991